← Back to Search

Behavioural Intervention

Transcranial Magnetic Stimulation for Schizophrenia

N/A
Recruiting
Research Sponsored by Northwell Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
DSM-V diagnosis of schizophrenia spectrum disorders
Male or female subjects 18 to 40 years of age
Must not have
Lifetime diagnosis of ataxia or other cerebellar disorders
Seizure history
Timeline
Screening 3 weeks
Treatment Varies
Follow Up end of 2nd week and 4th week
Awards & highlights

Summary

This trial is investigating the effects of 4-week rTMS treatment on brain and cognitive functions in patients with schizophrenia. Subjects will be randomized to receive either active or sham rTMS. fMRI scans, clinical assessments, and cognitive tests will be performed at baseline, end of the 2nd week, and end of the 4th week.

Who is the study for?
This trial is for individuals aged 18-40 with a diagnosis of schizophrenia spectrum disorders. It's not suitable for those with cerebellar disorders, recent TMS or ECT treatments, MRI contraindications, active medical conditions affecting cognition, substance abuse within six months, seizure history, or other major psychiatric or neurodegenerative diagnoses.
What is being tested?
The study tests the impact of Transcranial Magnetic Stimulation (rTMS) on brain and cognitive functions in schizophrenia patients over four weeks. Participants will either receive real rTMS plus standard care or sham rTMS (a placebo-like procedure) plus standard care to compare effects.
What are the potential side effects?
Possible side effects from rTMS may include discomfort at the stimulation site, headache, lightheadedness, seizures (very rare), and hearing changes if ear protection isn't used during treatment.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been diagnosed with a schizophrenia spectrum disorder.
Select...
I am between 18 and 40 years old.
Select...
I understand and can agree to the study's procedures and risks.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have been diagnosed with ataxia or another disorder affecting my balance and coordination.
Select...
I have a history of seizures.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~end of 2nd week and 4th week
This trial's timeline: 3 weeks for screening, Varies for treatment, and end of 2nd week and 4th week for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Cerebellar function
Secondary study objectives
Cognitive function
Other study objectives
Cerebellum-cognition associations

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: TMSExperimental Treatment1 Intervention
Group II: ShamPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Transcranial Magnetic Stimulation
2017
Completed Phase 4
~730

Find a Location

Who is running the clinical trial?

Northwell HealthLead Sponsor
473 Previous Clinical Trials
472,212 Total Patients Enrolled
28 Trials studying Schizophrenia
4,408 Patients Enrolled for Schizophrenia

Media Library

Transcranial Magnetic Stimulation (Behavioural Intervention) Clinical Trial Eligibility Overview. Trial Name: NCT05389787 — N/A
Schizophrenia Clinical Trial 2023: Transcranial Magnetic Stimulation Highlights & Side Effects. Trial Name: NCT05389787 — N/A
Transcranial Magnetic Stimulation (Behavioural Intervention) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05389787 — N/A
Schizophrenia Research Study Groups: TMS, Sham
~18 spots leftby Aug 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top